Figure 3
Pathway level changes associated with the potential duon mutation in TP53.
(A) Direct targets of TP53 and downstream pathways are shown, with expression patterns in the lung cancer cohorts super-imposed. Expression patterns of TP53 and its direct and indirect downstream targets were compared between the lung cancer samples that have TP53 R158L mutation (cases) and others (controls). If expression of a gene was systematically higher, lower, or comparable in the cases relative to controls, those are shown in red, green, or grey respectively. (B) The lung cancer samples that have TP53 p.R158L mutation were ranked based on the allelic expression of the mutant gene copy and indeed the direct and indirect downstream targets show consistent changes in expression. For instance, CDKN1A, which is the direct target of TP53, has reduced expression with an increase in the expression of the mutant copy of TP53.
